Abstract:Event Abstract Back to Event Optogenetics, electrophysiology and optical-imaging through windows on the brain in nonhuman primates. Octavio Ruiz1*, Edward M. Callaway2, Thomas D. Albright1, Anna W. Roe3, Brian R. Lustig3 and Gene R. Stoner1 1 Salk Institute for Biological Studies, VCL, United States 2 Salk Institute for Biological Studies, SNL, United States 3 Vanderbilt University, United States Non-human primate (NHP) models are essential for the study of human perception, cognition, motor control, and neurological diseases. Our laboratories study visual perception, and address questions of functional connectivity (within and across cortical areas), interactions between groups of neurons during object perception and attention, the interplay between different image cues (e.g. motion and depth), and cross-modal sensory interactions (auditory-visual). Our studies are conducted in anaesthethized and in awake-behaving NHPs using a diversity of techniques: optogenetics, single-cell electrophysiology, optical imaging, fluorescence imaging, anatomy, and psychophysics. We describe a new approach, developed in our laboratories, to improve optogenetics in NHPs. Optogenetics combines optics and genetics to control neuronal activity with cell-type specificity and millisecond temporal precision (1-4). Its use in model organisms such as rodents, drosophila, and C. Elegans is now well established. However, application of this technology in non-human primates (NHP) has been slow to develop (5-9). One key challenge has been the delivery of viruses and light to the brain through the thick dura mater of NHPs, which can only be penetrated with large-diameter devices that damage the brain. The opacity of the NHP dura prevents visualization of the underlying cortex, limiting the spatial precision of virus injections, electrophysiological recordings and photostimulation. Our approach replaces the native dura mater with an optically-transparent artificial dura. This artificial dura can be penetrated with fine glass micropipettes, enabling precisely targeted injections of virus into brain tissue with minimal damage to cortex. The expression of optogenetic agents can be monitored visually over time. Moreover, this optical window permits targeted, non-invasive photostimulation and concomitant measurements of neuronal activity via intrinsic signal imaging and electrophysiological recordings. These manipulations and measurements are precisely located in relation with the stable network of blood vessels on the surface of the brain (10, 11). We also describe our preliminary work to combine this multiple-technique information, and to share it between our laboratories, e.g.: registration of brain-surface images obtained at different times and with different techniques; linking photo-electrophysiological, epifluorescence and anatomical data; querying for specific combinations of sensory and optogenetic responses. We outline the interrelation between our project and other initiatives, and the possibility of using our artificial-dura implant to develop and test neuroinformatic resources in a medium-scale primate system. Acknowledgements This work was funded by R21 EY022853 (GRS, AWR), R01 EY020673 (EMC), and NIH NS044375 and P30EY008126 (AWR). References 1. Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci 8, 1263-8 (2005). 2. Chow, B. Y. et al. High-performance genetically targetable optical neural silencing by light-driven proton pumps. Nature 463, 98-102 (2010). 3. Fenno, L., Yizhar, O. & Deisseroth, K. The development and application of optogenetics. Annu Rev Neurosci 34, 389-412 (2011). 4. Han, X. & Boyden, E. S. Multiple-color optical activation, silencing, and desynchronization of neural activity, with single-spike temporal resolution. PLoS One 2, e299 (2007). 5. Diester, I. et al. An optogenetic toolbox designed for primates. Nat Neurosci 14, 387-97 (2011). 6. Galvan, A., Hu, X., Smith, Y. & Wichmann, T. In vivo optogenetic control of striatal and thalamic neurons in non-human primates. PLoS One 7, e50808 (2012). 7. Han, X. et al. A high-light sensitivity optical neural silencer: development and application to optogenetic control of non-human primate cortex. Front Syst Neurosci 5, 18 (2011). 8. Han, X. et al. Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron 62, 191-8 (2009). 9. Jazayeri, M., Lindbloom-Brown, Z. & Horwitz, G. D. Saccadic eye movements evoked by optogenetic activation of primate V1. Nat Neurosci 15, 1368-70 (2012). 10. Lustig, B. R. et al. Optogenetics through windows on the brain in nonhuman primates. Society for Neuroscience, Washington, DC. 229.09 (2012). 11. Ruiz, O. et al. Optogenetics through windows on the brain in the nonhuman primate. J.Neurophysiol. (Under review). Keywords: optogenetics, image registration, image reconstruction, fluorescence, Electrophysiology, optical imaging, Databases, Factual, neuronal circuits, Brain Mapping, Primates Conference: Neuroinformatics 2013, Stockholm, Sweden, 27 Aug - 29 Aug, 2013. Presentation Type: Poster Topic: General neuroinformatics Citation: Ruiz O, Callaway EM, Albright TD, Roe AW, Lustig BR and Stoner GR (2013). Optogenetics, electrophysiology and optical-imaging through windows on the brain in nonhuman primates.. Front. Neuroinform. Conference Abstract: Neuroinformatics 2013. doi: 10.3389/conf.fninf.2013.09.00031 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 30 Apr 2013; Published Online: 11 Jul 2013. * Correspondence: Dr. Octavio Ruiz, Salk Institute for Biological Studies, VCL, La Jolla, CA, United States, oruiz@salk.edu Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Octavio Ruiz Edward M Callaway Thomas D Albright Anna W Roe Brian R Lustig Gene R Stoner Google Octavio Ruiz Edward M Callaway Thomas D Albright Anna W Roe Brian R Lustig Gene R Stoner Google Scholar Octavio Ruiz Edward M Callaway Thomas D Albright Anna W Roe Brian R Lustig Gene R Stoner PubMed Octavio Ruiz Edward M Callaway Thomas D Albright Anna W Roe Brian R Lustig Gene R Stoner Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

Abstract:We have recently shown that bone marrow (BM) RNA profiles stratify patients with acute myeloid leukemia (AML) into immune-infiltrated and immune-depleted subtypes and that type I/II interferon (IFN)-related gene signatures associate with complete response to flotetuzumab (FLZ), an investigational CD123×CD3 bispecific DART molecule. Within the AML tumor microenvironment CD8+ T cells exhibit features of immune exhaustion and senescence (IES). IES are dysfunctional states driven by metabolic alterations in the tumor microenvironment (TME) and emerging targets for cancer immunotherapy. The aim of the current study was to determine whether IES predicts response of relapsed-refractory (R/R) AML to FLZ in the CP-MGD006-01 clinical trial. Based on prior knowledge and gene set enrichment analysis, we derived a 61-gene IES signature score from RNA-sequencing datasets (TCGA and Beat-AML Master Trial; 162 and 281 patients, respectively). The immunotherapy cohort included 139 BM samples from 71 patients with R/R AML treated with FLZ at the RP2D of 500 ng/kg/day (NCT02152956). BM samples were collected at time of study entry (n=71; n=66 with response data) and longitudinally post-cycle (PC)1 (n=40), PC2 (n=18), PC3 and 4 (n=4) and end of treatment (n=6). AML status at study entry was classified as primary induction failure (PIF, defined as lack of response to at least 2 induction treatment cycles), and early (ER) or late relapse (LR), defined as complete remission (CR) of <6-month or ≥6-month duration, respectively. Overall response rate (ORR), collectively complete response, was defined as <5% BM blasts (CR, CRh, CRi or MLFS), and partial response (PR) was defined as >50% decrease or decrease to 5-25% BM blasts. RNAs were profiled on the PanCancer IO 360TM gene expression panel on the nCounter® platform. Formalin-fixed paraffin embedded BM biopsies were profiled using the human IO protein and RNA panels on the GeoMx® digital spatial profiler (DSP). The 61 genes in the IES signature included T/NK-cell markers (granzymes, CD8A, KLRD1, KLRK1), immune checkpoints (ICOS, CTLA4, EOMES), IFNG and IFN-stimulated genes (CXCR6, IFIH1, IL10RA, GBP1), and were enriched in KEGG pathways related to Th1/Th2 differentiation, TCR signaling, cytokine-cytokine receptor interaction, NK-mediated cytotoxicity and CD28 costimulation (false discovery rate<0.001 for all; Fig. 1A). Unsupervised hierarchical clustering of gene expression allowed the identification of BM samples with high, intermediate and low IES scores at time of study enrollment (Fig. 1B). Ninety-five percent (18/19) of patients in the IEShigh cluster had PIF/ER AML, congruent with prior studies showing enhanced immune infiltration and IFN signaling in the TME of patients with PIF. Notably, ORR to FLZ (complete response, n=18 or PR, n=5) were documented in 11/19 (58%), 10/32 (31.2%) and 2/15 (13.3%) of patients in the IEShigh, IESint and IESlow cluster, respectively (Fig. 1B). The IES signature score was significantly higher at baseline in patients who responded to FLZ compared with non-responders (P=0.0052; Fig. 1C). High-dimensional flow cytometry of sequential BM samples collected at time of study entry and PC1 of FLZ showed the on-treatment upregulation on both CD4 and CD8 T cells of early activation markers CD69 and CD38 (but not the late activation marker HLA-DR), as well as immune checkpoints LAG3 and Tim-3, and proliferation marker Ki-67, indicating FLZ-mediated modulation of the immune TME. To determine the variation in co-expression of T-cell markers associated with FLZ treatment, we also measured lymphocytes obtained from 21 BM samples prior to and post-FLZ using an unsupervised multivariate analysis. Qualitative comparisons of the principal component analysis (PCA) showed distinct phenotypic changes in BM samples post-treatment (Fig. 1D). Characterization of BM biopsies using GeoMx DSP showed distinct T-cell clustering in responders (Fig. 1E). PCA showed enhanced CD45, CD3, CD4 and PDL1 in situ RNA/protein expression (fold change 1.96, 2.83, 3.32, 4.7, respectively, P<0.05 for all) at PC1 of FLZ in OR versus non-responders (Fig. 1F). In conclusion, features of IES were associated with response to FLZ. T-cell functional rejuvenation by FLZ could benefit patients with R/R AML by counteracting pre-existing immune dysfunction. Figure Disclosures Church: NanoString Technologies, Inc.: Current Employment. Uy:Pfizer: Consultancy; Agios: Consultancy; Genentech: Consultancy; Jazz Pharmaceuticals: Consultancy; Astellas Pharma: Honoraria; Daiichi Sankyo: Consultancy. Emadi:Genentech: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; NewLink Genetics: Research Funding; Jazz Pharmaceuticals: Research Funding; KinaRx: Other: co-founder and scientific advisor; Servier: Membership on an entity's Board of Directors or advisory committees. Walter:Aptevo Therapeutics: Research Funding. Foster:Bellicum Pharmaceuticals: Research Funding; Macrogenics: Consultancy, Research Funding; Daiichi Sankyo: Consultancy. Arellano:Cephalon Oncology: Research Funding; Hanmi: Research Funding; Gilead Sciences, Inc: Consultancy, Membership on an entity's Board of Directors or advisory committees. Wieduwilt:Amgen: Research Funding; Leadiant: Research Funding; Merck: Research Funding; Shire: Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Macrogeneics: Research Funding. Michaelis:Jazz Pharmaceuticals: Research Funding. Stiff:Kite, a Gilead Company: Research Funding; Gamida Cell: Research Funding; Atara: Research Funding; Unum: Research Funding; Delta-Fly: Research Funding; Macrogenics: Research Funding; Amgen: Research Funding. Advani:Takeda: Research Funding; Immunogen: Research Funding; Glycomimetics: Consultancy, Other: Steering committee/ honoraria, Research Funding; Macrogenics: Research Funding; Abbvie: Research Funding; Seattle Genetics: Other: Advisory board/ honoraria, Research Funding; Amgen: Consultancy, Other: steering committee/ honoraria, Research Funding; Kite: Other: Advisory board/ honoraria; Pfizer: Honoraria, Research Funding; Novartis: Consultancy, Other: advisory board; OBI: Research Funding. Wermke:MacroGenics: Honoraria. Erba:AbbVie, Daiichi Sankyo, Forma, ImmunoGen, Jazz Pharmaceuticals, MacroGenics, Novartis, PTC: Research Funding; AbbVie, Agios, Celgene, Incyte, Jazz Pharmaceuticals, and Novartis: Speakers Bureau; AbbVie, Agios, Amgen, Astellas, Celgene, Daiichi Sankyo, Glycomimetics, ImmunoGen, Incyte, Jazz Pharmaceuticals, MacroGenics, Novartis, and Pfizer: Consultancy; Glycomimetics: Other: member of Scientific Steering Committee; Celgene: Other: chair of the Scientific Steering Committee; Covance (AbbVie): Other: chair of the Independent Review Committee. Ravandi:Orsenix: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Macrogenics: Research Funding; Xencor: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria. Topp:Amgen, KITE, Novartis, Regeneron, Roche: Consultancy; Amgen, Boehringer Ingelheim, KITE, Regeneron, Roche: Research Funding. Muth:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Kaminker:MacroGenics, Inc.: Current Employment, Current equity holder in publicly-traded company. Gojo:Amgen: Research Funding; Merck: Research Funding; Amphivena: Research Funding; Genentech: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees. Luznik:AbbVie: Consultancy; WindMil Therapeutics: Patents & Royalties: Patent holder; Merck: Research Funding, Speakers Bureau; Genentech: Research Funding. DiPersio:Magenta Therapeutics: Membership on an entity's Board of Directors or advisory committees. Davidson-Moncada:Macrogenics: Current Employment. Rutella:NanoString Technologies, Inc.: Research Funding; MacroGenics, Inc.: Research Funding; Kura Oncology: Research Funding.

Integrative Microscopy Approaches Reveal Specialized Signaling Filopodia Promote Morphogen Gradient Formation during Mammalian Development.

A Serotonergic Axon-Cilium Synapse Drives Nuclear Signaling to Maintain Chromatin Accessibility.

Author Correction: Failure of Human Rhombic Lip Differentiation Underlies Medulloblastoma Formation

Coronary Plaque Sampling Reveals Molecular Insights Into Coronary Artery Disease

Cryogenic Electron Ptychographic Single-Particle Analysis (Cryo-Epty SPA)

St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem

Growth-Hormone Receptors - Their Structure, Location And Role

Abstract 3771: 3D correlated multi-scale cellular and molecular architecture of solid tumors

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Supplementary Methods, Figures 1-14 from A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens

Abstract LB071: A phenomics platform combining imaging and artificial intelligence for rapid validation and advancement of novel oncology targets

MODL-26. CHILDREN’S BRAIN TUMOR NETWORK: ACCELERATING RESEARCH THROUGH COLLABORATION AND OPEN-SCIENCE

Abstract A002: Dissecting the brain metastatic microenvironment to uncover immune and molecular correlates of response to immunotherapy

Optogenetics, Electrophysiology and Optical-Imaging Through Windows on the Brain in Nonhuman Primates.

Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials

Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts

Correction: MEIS-WNT5A Axis Regulates Development of Fourth Ventricle Choroid Plexus.

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Abstract 3649: A novel spatial multi-omic approach for biological discoveries in colonic diseased tissues using a comprehensive Immuno-Oncology Proteome Atlas and Whole Transcriptome Atlas

Abstract 1163: Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS